One clinical trial (NCT01309789) showed that a CD30 antibody, namely brentuximab vedotin (BV), resulted in stable remission in patients with CD30-positive peripheral T-cell lymphoma. Here, TNFRSF8 is linked to peripheral T-cell lymphoma, not otherwise specified.